List of Excipients in Branded Drug COCAINE HYDROCHLORIDE NASAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lannett Company Inc	COCAINE HYDROCHLORIDE NASAL	cocaine hydrochloride nasal	0527-1971	CITRIC ACID MONOHYDRATE	2037-02-07
Lannett Company Inc	COCAINE HYDROCHLORIDE NASAL	cocaine hydrochloride nasal	0527-1971	D&C YELLOW NO. 10	2037-02-07
Lannett Company Inc	COCAINE HYDROCHLORIDE NASAL	cocaine hydrochloride nasal	0527-1971	FD&C GREEN NO. 3	2037-02-07
Lannett Company Inc	COCAINE HYDROCHLORIDE NASAL	cocaine hydrochloride nasal	0527-1971	SODIUM BENZOATE	2037-02-07
Lannett Company Inc	COCAINE HYDROCHLORIDE NASAL	cocaine hydrochloride nasal	0527-1971	WATER	2037-02-07
OMNIVIUM PHARMACEUTICALS LLC	COCAINE HYDROCHLORIDE NASAL	cocaine hydrochloride nasal	81665-301	CITRIC ACID MONOHYDRATE	2037-02-07
OMNIVIUM PHARMACEUTICALS LLC	COCAINE HYDROCHLORIDE NASAL	cocaine hydrochloride nasal	81665-301	D&C YELLOW NO. 10	2037-02-07

Excipient Strategy and Commercial Opportunities for Cocaine Hydrochloride Nasal

Last updated: February 25, 2026

What are the key excipient considerations for cocaine hydrochloride nasal formulations?

Cocaine hydrochloride nasal products require excipients that optimize stability, absorption, and patient comfort. The primary roles of excipients include enhancers for mucosal absorption, stabilizers, preservatives, and agents to mitigate irritation.

Key excipients:

• Buffering agents (e.g., sodium citrate, phosphate buffers) maintain pH around 4.5–6.0, optimizing absorption and reducing mucosal irritation.
• Preservatives (e.g., phenylethyl alcohol, benzalkonium chloride) prevent microbial growth, especially in multi-use formulations.
• Vasoconstrictors (e.g., epinephrine) are not typical but may be used in combination products for adjunctive effects or local anesthesia.
• Solubilizers (e.g., sodium chloride) ensure proper dissolution of the product.
• Humectants (e.g., glycerol) increase viscosity and improve patient tolerability.

Challenges:

• Mucosal irritation: Need for buffering systems and soothing agents to reduce irritation.
• Drug stability: Cocaine's sensitive nature necessitates stabilizers to prevent degradation.
• Shelf life: Preservatives and stabilizers extend product usability.

How does excipient choice influence regulatory and commercial success?

Regulatory pathways demand safety and efficacy validation of excipients, especially due to the drug's controlled substance status. Excipients must be pharmaceutically acceptable and compliant with pharmacopeial standards (USP, EP).

Commercial success hinges on:

• Ease of manufacturing: Excipients that are readily available and cost-effective.
• Patient compliance: Non-irritating excipient profiles lead to better tolerability.
• Market differentiation: Formulations with optimized excipients can claim superior absorption or reduced side effects.

What are the current regulatory considerations for cocaine hydrochloride nasal formulations?

• Controlled substance regulations: Cocaine is Schedule II in the US, requiring DEA registration and strict manufacturing practices.
• Excipient approval: Excipients must be pre-approved by regulatory bodies; use of novel excipients risks delays.
• Good manufacturing practices (GMP): Ensuring consistent quality and traceability.

What commercial opportunities exist for innovative formulations?

• Reformulations with reduced irritancy: New excipient combinations offering lower mucosal damage improve patient acceptability.
• Extended-release nasal sprays: Incorporating polymers (e.g., hydroxypropyl methylcellulose) for prolonged drug action.
• Combination products: Pairing cocaine with local anesthetics or vasoconstrictors to broaden therapeutic indications.
• Specialty markets: Market for controlled diagnostic or research applications, especially in forensic and clinical settings.

Strategic considerations for market entry and growth:

• Develop excipient matrices that enhance stability and absorption.
• Leverage existing pharmacopeial excipients to accelerate regulatory clearance.
• Highlight tolerability improvements and novel delivery features in marketing.
• Establish partnerships to navigate complex regulatory and distribution landscapes.

Key Takeaways

• Excipient selection for cocaine hydrochloride nasal formulations focuses on stability, mucosal tolerance, and absorption enhancement.
• Regulatory compliance limits the use of novel excipients, emphasizing the need for pharmacopeial standards.
• Commercial opportunities include new formulations with better tolerability, extended-release options, and combination products.
• Addressing regulatory and manufacturing challenges creates pathways for niche and specialized markets.

FAQs

1. Can excipients in cocaine hydrochloride nasal formulations include novel or unapproved substances?
No. Regulatory approval generally requires excipients to be pharmacopeially approved and deemed safe for nasal use, especially given cocaine’s controlled status.

2. What are the main regulatory hurdles for nasal cocaine formulations?
Controlled substance scheduling, strict manufacturing standards, and demonstration of excipient safety contribute to regulatory hurdles.

3. How do excipients affect the shelf stability of cocaine nasal products?
Preservatives prevent microbial contamination, buffering agents prevent pH-induced degradation, and stabilizers mitigate chemical instability.

4. Are there opportunities for non-controlled, over-the-counter derivatives?
No; cocaine's Schedule II classification restricts formulations to authorized medical or research contexts only.

5. How can formulation changes impact market differentiation?
Innovations that reduce irritation, extend drug action, or enable combination therapy can improve patient compliance and create competitive advantages.

---

References

1. U.S. Food and Drug Administration. (2022). Guidance for Industry: Nasal Spray Products.
2. European Pharmacopoeia. (2023). Cocaine Hydrochloride.
3. DEA. (2021). Controlled Substance Schedules.
4. World Health Organization. (2018). Guidelines on the Pharmacological Use and Abuse of Cocaine.
5. International Pharmaceutical Excipients Council. (2020). Safety Standards for Excipients in Nasal Formulations.